PACTR202011523101903Other3 期
Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older. COVID-19
未提供0 个研究点目标入组 34,520 人开始时间: 2020年11月2日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- Other
- 入组人数
- 34,520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •Participants are eligible for the study only if all of the following criteria are met:
- •I01: Aged 18 years or older on the day of inclusion
- •I02: A female participant is eligible to participate if she is not pregnant or breastfeeding
- •and one of the following conditions applies:
- •Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile.
- •Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the second vaccination.
- •A subject of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 4 hours before any dose of study intervention.
- •I03: Informed consent form has been signed and dated
- •I04: Able to attend all scheduled visits and to comply with all trial procedures
- •I05: Covered by health insurance, only if required by local, regional or national regulations
- •I06: SARS-CoV-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of SARS-CoV-2 antibodies
- •I07: For persons living with human immunodeficiency virus (HIV), stable HIV infection determined by participant currently on ARVs with CD4 count > 200/mm3
排除标准
- •Participants are not eligible for the trial if any of the following criteria are met:
- •E01: Participation at the time of trial enrollment (or in the 30 days preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- •E02: Receipt of any vaccine in the 30 days preceding or on the day of the first trial vaccination or planned receipt of any vaccine in the 30 days following the second trial vaccination except for influenza vaccination, which may be received at any time in relation to trial intervention a.
- •E03: Prior administration of a coronavirus vaccine (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], SARS-CoV, Middle East Respiratory Syndrome [MERS-CoV])
- •E04: Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances b.
- •E05: Dementia or any other cognitive condition at a stage that could interfere with following the trial procedures based on Investigator or designee’s judgment
- •E06: Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based on Investigator or designee’s judgment
- •E07: Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating IM vaccination based on Investigator or designee’s judgment
- •E08: Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- •E09: Unstable acute or chronic illness that in the opinion of the Investigator or designee poses additional risk as a result of participation or that could interfere with the trial procedures
- •E10: Receipt of solid-organ or bone marrow transplants in the past 180 days
- •E11: Receipt of anti-cancer chemotherapy in the last 90 days
研究者
相似试验
已完成
不适用
Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in liver transplant recipientsImmunogenicity and safety of SARS-CoV-2 vaccine in liver transplant recipientsliver transplant, vaccine, COVID-19, SARS-CoV-2, safetyTCTR20210526004Faculty of medicine, Chulalongkorn university60
尚未招募
不适用
Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in patients with hepatocellular carcinomaImmunogenicity and safety of SARS-CoV-2 vaccine in patients with hepatocellular carcinomaCOVID-19, vaccine, hepatocellular carcinoma, SARS-CoV-2TCTR20210525005Faculty of Medicine, Chulalongkorn university60
进行中（未招募）
1 期
Study of Recombinant Protein Vaccines with Adjuvant as a Primary Series and as a Booster Dose against COVID-19 in Adults 18 Years of Age and OlderCOVID-19MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-003370-41-ESSanofi Pasteur Inc.5,412
招募中
4 期
COVID-19 vaccination in patients of Inflammatory Bowel DiseaseCTRI/2022/04/041882ICMR
招募中
1 期
Phase I clinical trial of Osvid-19 inactivated vaccine for Covid-19 (Osve Pharmaceutical Company)COVID-19 disease.COVID-19, virus identifiedU07.1IRCT20210622051670N1Osve pharmaceutical company40